Steven Cohen’s Actinium Pharmaceuticals ATNM Stock Holding History

Steven Cohen’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,295	Closed	-$14K	–	3769
2025 Q4	$14K	Buy	+10,295	New	+$15K	﹤0.01%	3840

Other funds holding ATNM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's ATNM Position: Q1 2026 in Review

Steven Cohen sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 10,295 shares — an estimated $14K sold.

Steven Cohen first reported a position in ATNM in Q4 2025 and held it in 1 quarter. The position peaked at $14K in Q4 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

Steven Cohen reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Steven Cohen sold 10,295 Actinium Pharmaceuticals shares in Q1 2026, an estimated $14K.
Steven Cohen first reported a position in Actinium Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Steven Cohen's Actinium Pharmaceuticals position peaked at $14K in Q4 2025.
54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.